BDSX News and Press, Biodesix Inc. From 11/14/23

Capillary device supports in-office blood collection in diverse practice locations without the need for venipuncture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collectin...

2023-11-11 13:24:02 ET Biodesix, Inc. (BDSX) Q3 2023 Earnings Conference Call November 7, 2023 16:30 ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Ca...

2023-11-10 10:00:06 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum ...

2023-11-07 16:31:13 ET More on Biodesix Seeking Alpha’s Quant Rating on Biodesix Historical earnings data for Biodesix Financial information for Biodesix For further details see: Biodesix GAAP EPS of -$0.14 beats by $0.01, revenue of $13.5M misses ...

Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit margin of 76% versus 67% for the third quarter 2022 and 73% for the second quarter of 2023; Net loss, which includes certa...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Biodesix Inc. (BDSX) is expected to report $-0.15 for Q3 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix’s management will host a c...

Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules. Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced th...